Moderna to launch phase III trials for mRNA cancer vaccine
US biotech firms Moderna and Merck are collaborating together on an mRNA-based cancer vaccine, based on the mRNA technology used in Moderna’s COVID-19 vaccine, and are set to move into phase III trials next year. The experimental vaccine made by Moderna is being coupled with Merck’s own immunotherapy medication known as Keytruda in order to […]
Continue Reading